All episodes

In this episode, Professor Francesco Giorgino (EASD President) and Professor Leszek Czupryniak (EASD Global Council Advisor) introduce EASD's newest initiative: the Global Council, launched in Madrid in 2023. This 13-member council brings together diabetes experts from Asia, North and South America, Africa, the Middle East, Australia, and underrepresented regions of Europe to provide direct, active contributions to EASD activities and address global challenges in diabetes research and care.

The conversation addresses the urgent importance of diversity in diabetes data and research, particularly as political movements in some regions actively discourage it and explains how registries are essential for understanding diabetes...

In this episode, a cardiologist, an epidemiologist and a diabetologist come together to discuss the deep and evolving links between diabetes and cardiovascular disease. The conversation explores heart failure as a common but often under-recognized complication of diabetes, how cardiovascular risk begins even before type 2 diabetes develops, and why modern therapies increasingly target multiple organs at once. The speakers highlight the importance of early detection, collaboration across specialties, and prevention as populations age and chronic disease patterns shift.

In this episode, Prof. Frédéric Gachon and Prof. Olga Pivovarova-Ramich explore how the timing of eating and exercise influences metabolism and diabetes risk. Drawing on recent research in chronobiology, they discuss circadian rhythms, chronotype, late-night eating, intermittent fasting, and how aligning daily behaviours with our internal clocks may improve metabolic health and insulin sensitivity.

Prof. Gachon and and Prof. Pivovarova-Ramich explore how eating late or at the wrong time disrupts your body’s rhythm, and how different chronotypes (early risers vs night owls) respond to meal timing. They also touch on the growing popularity of intermittent fasting and time-restricted eating, as...

In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes.

EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes...

In our first episode of 2026, Prof. Hindrik Mulder, Editor-in-Chief of Diabetologia, offers a journal’s-eye view of the most exciting and challenging developments in diabetes research today.

Drawing on his unique overview of submissions from across the global research community, prof. Mulder discusses emerging breakthroughs such as hypoimmune stem cell-based therapies that are transforming from theoretical possibilities into scalable, off-the-shelf treatments for diabetes. Prof. Mulder discusses how these innovations could revolutionise diabetes care by overcoming the historical barriers of islet transplantation.

We further explore Diabetologia's special 2025 issue on "Opportunities and Challenges in Diabetes," which tackles the critical issues of...

In this episode, Dr. Tamara Hannon (Indiana University Health) and Prof. Martin Wabitsch (Universtätsklinikum Ulm) unpack the findings of the SURPASS-PEDS trial - the first study to evaluate the dual GIP/GLP-1 receptor agonist tirzepatide in adolescents with type 2 diabetes.

With youth-onset type 2 diabetes rising sharply across the US and Europe, and with young people experiencing faster beta-cell decline, more severe obesity, and greater socioeconomic burdens, the need for effective therapies has never been greater. They discuss why adolescent disease differs fundamentally from adult type 2 diabetes, why weight-loss expectations cannot be compared across age groups, and how tirzepatide...

In this episode, EASD presents its inaugural clinical guideline on diabetes distress. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management) and why routine assessment and supportive care must become part of standard practice.

The guideline sets out eight good practice statements to help clinicians normalise conversations about emotional wellbeing, plus graded recommendations for managing distress in adults with type 1 and type 2 diabetes. Psychological interventions...

In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes.

They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers.

From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in...

Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes.

The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes...

At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observed with injectable GLP-1 formulations.

The discussion highlights the potential impact of an oral agent on clinical practice, including improved accessibility, suitability for older adults, and earlier use in the treatment pathway. Dr Busui also reviews new data on heart failure phenotypes, particularly...